An observational study in Cardiogenic Shock and Acute Coronary Event, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Shock, Cardiogenic with a site in Italy — 10 open to participants now, 12 under way, none of them phase 3. Shock, Cardiogenic · Italy.
Among the 20 studies in Shock, Cardiogenic with a site in Italy, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2022, is one of 14 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 20th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →10 of the 20 studies in Shock, Cardiogenic with a site in Italy are open now. Recruiting first, the newest first:
Fondazione GISE Onlus · Sites in Italy
Ages 18–75
Abiomed Inc. · Sites in Italy, Germany, Switzerland
Ages 18+
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 18–110
IRCCS San Raffaele · Sites in Italy
Ages 18+
Federico II University · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 70 across the 6 interventional studies, 500 across the 14 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.
IRCCS Azienda Ospedaliero-Universitaria di Bologna has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Cardiogenic with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT06827314IRCCS Azienda Ospedaliero-Universitaria di BolognaPharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network Model for the Management of Cardiogenic Shock | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Shock, Cardiogenic with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to understand and describe the epidemiology of cardiogenic shock in Emilia Romagna with a specific focus on outcome stratified by aetiologies, sex and age. The main outcomes are:
This is an observational study without intervention. Patients will be treated according to current clinical practice, according to physician judgment and data sheets of each drug used according to clinical practice.
This is a multicenter observational study with both a retrospective and a prospective cohort.
Study population will include all consecutive patients diagnosed with cardiogenic shock and admitted to the cardiac intensive care unit of the participating centers.
For the patients enrolled at IRCCS Azienda Ospedaliera-Universitaria di Bologna this study will involve a collaboration with UO Cardiologia.
For the retrospective cohort, patients will be selected based on ICD9 discharge codes and included if they fulfill inclusion criteria after review of hospital charts. The retrospective cohort will serve as a historical comparison regarding epidemiology, treatment strategies and survival.
Incidence and workload burden of CICU will be studied comparing the number of CS patients and the total number of admissions in the study period.
For the prospective cohort, study population consists of all consecutive patients diagnosed with CS and admitted to participating CICUs in the Emilia Romagna region. For the prospective cohort patients will be enrolled after study approval and until 31 December 2027.
Patients will be enrolled upon admission or at the development of CS if already admitted.
Retrospective data will be collected for five years, starting from January 1st 2018 until the starting date of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of CS over the total CICU admissions stratified by aetiologies, sex and age.
Incidence
Time frame: 5 years
Length of hospitalization, stratified by aetiologies, sex and age.
Days
Time frame: 5 years
CS-related in-hospital mortality stratified by aetiologies, sex and age.
Incidence
Time frame: 5 years
Epidemiology of patients admitted with CS, regarding age, gender, etiology and modality of presentation (acute or acute on chronic), echocardiographic and haemodynamic data, treatment strategy with inotropes and/or short-term MCS, cardiac arrest.
Demography description
Time frame: 5 years
Recovery from cardiogenic shock, defined as improvement to at least SCAI stage B or discharge from CICU to a step-down ward
Recovery from cardiogenic shock
Time frame: 5 years
In-hospital survival according to age, etiology, presentation (acute or acute on chronic) and modality of treatment (inotropes or MCS).
In-hospital survival
Time frame: 5 years
Rate and reason of unplanned re-hospitalizations within one month after primary discharge
Rate and reason of unplanned re-hospitalizations
Time frame: 5 years
Workload burden will be estimated as the percentage of CS admission and the mean duration of CICU stay as compared to other admissions during study period
Workload burden
Time frame: 5 years
Rate of adherence to several items and differences between older era (retrospective data) and prospective cohort
Blood counts, ECG, oxygen saturation and respiratory monitoring.
Time frame: 5 years
Rate of successful bridge to heart replacement therapy (heart transplant or LVAD implant) in patients potentially eligible (i.e. age < 71 years old) and transferred to IRCCS Policlinico S.Orsola hub center.
Rate of successful bridge to heart replacement therapy
Time frame: 5 years
Comparison of survival between patients who underwent HRT as a consequence of CS to elective patients in the study period
Comparison of survival
Time frame: 5 years
Description of in-hospital complications such as rate of renal replacement therapy, number of nosocomial infections with therapy and consequent associated mortality.
Description of in-hospital complications
Time frame: 5 years
Description of MCS-related complications, including bleeding requiring transfusions, vascular complications including bleeding requiring intervention and limb ischemia.
Description of MCS-related complications
Time frame: 5 years
Started Dec 2022 (actual). Primary completion is estimated for Nov 2027, 59 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 59 months is above that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →